已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

医学 吉西他滨 内科学 养生 克拉斯 胰腺癌 胃肠病学 临床终点 安慰剂 尼妥珠单抗 无进展生存期 临床研究阶段 随机对照试验 外科 肿瘤科 癌症 毒性 化疗 表皮生长因子受体 病理 结直肠癌 替代医学
作者
Beate Schultheis,Dirk Reuter,M. Ebert,Jens T. Siveke,Andrea Kerkhoff,Wolfgang E. Berdel,Ralf‐Dieter Hofheinz,Dirk Behringer,Wolfgang E. Schmidt,Erdem Göker,Sara De Dosso,Michael Kneba,Şuayib Yalçın,Friedrich Overkamp,Frank Schlegel,Markus Dommach,Robert Rohrberg,Tilmann Steinmetz,Michael Bulitta,Dirk Strumberg
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:28 (10): 2429-2435 被引量:121
标识
DOI:10.1093/annonc/mdx343
摘要

ABSTRACT

Background

This randomized study was designed to investigate the superiority of gemcitabine (gem) plus nimotuzumab (nimo), an anti-epidermal growth factor receptor monoclonal antibody, compared with gem plus placebo as first-line therapy in patients with advanced pancreatic cancer.

Patients and methods

Patients with previously untreated, unresectable, locally advanced or metastatic pancreatic cancer were randomly assigned to receive gem: 1000 mg/m2, 30-min i.v. once weekly (d1, 8, 15; q29) and nimo: fixed dose of 400 mg once weekly as a 30-min infusion, or gem plus placebo, until progression or unacceptable toxicity. The primary end point was overall survival (OS), secondary end points included time to progression, overall response rate, safety and quality of life.

Results

A total of 192 patients were randomized, with 186 of them being assessable for efficacy and safety (average age 63.6 years). One-year OS/progression-free survival (PFS) was 34%/22% for gem plus nimo compared with 19%/10% for gem plus placebo (HR = 0.69;P = 0.03/HR = 0.68;P = 0.02). Median OS/PFS was 8.6/5.1 months for gem plus nimo versus 6.0/3.4 mo in the gem plus placebo group (HR = 0.69;P = 0.0341/HR = 0.68;P = 0.0163), with very few grade 3/4 toxicities.KRAS wildtype patients experienced a significantly better OS than those withKRAS mutations (11.6 versus 5.6 months,P = 0.03).

Conclusion

This randomized study showed that nimo in combination with gem is safe and well tolerated. The 1-year OS and PFS rates for the entire population were significantly improved. Especially, those patients withKRAS wildtype seem to benefit. The study was registered as protocol ID OSAG101-PCS07, NCT00561990 and EudraCT 2007-000338-38.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赖茜发布了新的文献求助10
刚刚
answer答案完成签到,获得积分10
2秒前
4秒前
隐形曼青的应助被墨苒采纳,获得10
6秒前
知云完成签到 ,获得积分10
7秒前
某某完成签到 ,获得积分10
7秒前
GingerF的应助被科研通管家采纳,获得60
8秒前
顾矜的应助被科研通管家采纳,获得10
8秒前
天天快乐的应助被科研通管家采纳,获得10
8秒前
8秒前
molihuakai的应助被科研通管家采纳,获得10
8秒前
星辰大海的应助被科研通管家采纳,获得10
8秒前
8秒前
8秒前
华仔的应助被科研通管家采纳,获得10
9秒前
在水一方的应助被科研通管家采纳,获得10
9秒前
9秒前
Nole的应助被科研通管家采纳,获得30
9秒前
Jasper的应助被科研通管家采纳,获得10
9秒前
情怀的应助被科研通管家采纳,获得10
9秒前
Lucas的应助被科研通管家采纳,获得10
9秒前
Nole的应助被科研通管家采纳,获得30
9秒前
幸福完成签到 ,获得积分10
10秒前
11秒前
12秒前
微山发布了新的文献求助10
13秒前
小贺y完成签到 ,获得积分10
13秒前
oaix完成签到 ,获得积分10
14秒前
15秒前
欢呼的糖豆完成签到,获得积分10
15秒前
可欣发布了新的文献求助10
16秒前
16秒前
熙熙攘攘完成签到,获得积分10
17秒前
17秒前
17秒前
17秒前
17秒前
VDC的应助被我看看怎么个事采纳,获得30
17秒前
17秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054